What do systematic reviews say?

Epoetin alpha every 2 weeks vs to weekly

• Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 798 participants
  Low

Epoetin alpha every 2 weeks vs to weekly

Epoetin alpha every 2 weeks may leads to lower number reaching target Hb compared with to weekly (low certainty).

• Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
  RR 0.96 [0.93, 0.99]
  4 studies · 798 participants
  Low

Epoetin alpha every 2 weeks vs to weekly

Epoetin alpha every 2 weeks showed no clear difference in number of deaths compared with to weekly (low certainty).

• Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
  RR 0.89 [0.38, 2.07]
  4 studies · 838 participants
  Low

Epoetin alpha every 2 weeks vs to weekly

Epoetin alpha every 2 weeks showed no clear difference in adverse events: RBC transfusions compared with to weekly (low certainty).

• Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
  RR 1.56 [0.71, 3.45]
  3 studies · 580 participants
  Low

Epoetin alpha every 2 weeks vs to weekly

Epoetin alpha every 2 weeks showed no clear difference in adverse events: hypertension compared with to weekly (moderate certainty).

• Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
  RR 0.85 [0.55, 1.32]
  4 studies · 838 participants
  Moderate

Epoetin alpha every 2 weeks vs to weekly

Epoetin alpha every 2 weeks showed no clear difference in adverse events: thrombovascular events compared with to weekly (low certainty).

• Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients 2017 · Cochrane Headline outcomes only
  RR 1.41 [0.67, 3]
  4 studies · 838 participants
  Low